{"id":1620,"date":"2024-02-14T07:21:35","date_gmt":"2024-02-14T06:21:35","guid":{"rendered":"https:\/\/ocvigilance.com\/the-ema-has-published-version-1-2-of-the-document-guidance-on-the-electronic-submission-of-information-on-investigational-medicinal-products-for-human-use-in-the-xevmpd-t1-t2-t3\/"},"modified":"2024-11-04T14:36:16","modified_gmt":"2024-11-04T14:36:16","slug":"the-ema-has-published-version-1-2-of-the-document-guidance-on-the-electronic-submission-of-information-on-investigational-medicinal-products-for-human-use-in-the-xevmpd-t1-t2-t3","status":"publish","type":"post","link":"https:\/\/ocvigilance.com\/en\/the-ema-has-published-version-1-2-of-the-document-guidance-on-the-electronic-submission-of-information-on-investigational-medicinal-products-for-human-use-in-the-xevmpd-t1-t2-t3\/","title":{"rendered":"The EMA has published version 1.2 of the document &#8216;Guidance on the electronic submission of information on investigational medicinal products for human use in the XEVMPD&#8217; (T1, T2, T3)."},"content":{"rendered":"\n<div class=\"wp-block-buttons is-content-justification-center is-layout-flex wp-container-core-buttons-is-layout-3e41869c wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button has-custom-width wp-block-button__width-50\"><a class=\"wp-block-button__link has-background wp-element-button\" href=\"\/wp-content\/uploads\/2024\/06\/La-EMA-ha-publicado-la-version-1.2-del-documento-Guidance-on-the-electronic-submission-of-information-on-investigational-medicinal-products-for-human-use-in-the-XEVMPD.-T1-T2-T3-.pdf\" style=\"border-radius:5px;background-color:#004667\">View PDF<\/a><\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":1486,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12,23],"tags":[],"class_list":["post-1620","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-medicamentos-de-uso-humano","category-medicines-for-human-use"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Guidance on the electronic submission of information on investigational medicinal products for human use in the XEVMPD | OC Vigilance<\/title>\n<meta name=\"description\" content=\"The EMA has published version 1.2 of the document &#039;Guidance on the electronic submission of information on investigational medicinal products for human use in the XEVMPD&#039; (T1, T2, T3) All the information!\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ocvigilance.com\/en\/the-ema-has-published-version-1-2-of-the-document-guidance-on-the-electronic-submission-of-information-on-investigational-medicinal-products-for-human-use-in-the-xevmpd-t1-t2-t3\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Guidance on the electronic submission of information on investigational medicinal products for human use in the XEVMPD | OC Vigilance\" \/>\n<meta property=\"og:description\" content=\"The EMA has published version 1.2 of the document &#039;Guidance on the electronic submission of information on investigational medicinal products for human use in the XEVMPD&#039; (T1, T2, T3) All the information!\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ocvigilance.com\/en\/the-ema-has-published-version-1-2-of-the-document-guidance-on-the-electronic-submission-of-information-on-investigational-medicinal-products-for-human-use-in-the-xevmpd-t1-t2-t3\/\" \/>\n<meta property=\"og:site_name\" content=\"OC Vigilance\" \/>\n<meta property=\"article:published_time\" content=\"2024-02-14T06:21:35+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-04T14:36:16+00:00\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/ocvigilance.com\\\/en\\\/the-ema-has-published-version-1-2-of-the-document-guidance-on-the-electronic-submission-of-information-on-investigational-medicinal-products-for-human-use-in-the-xevmpd-t1-t2-t3\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ocvigilance.com\\\/en\\\/the-ema-has-published-version-1-2-of-the-document-guidance-on-the-electronic-submission-of-information-on-investigational-medicinal-products-for-human-use-in-the-xevmpd-t1-t2-t3\\\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\\\/\\\/ocvigilance.com\\\/#\\\/schema\\\/person\\\/1305e83051c56e0ccbcdbf88c278aa8f\"},\"headline\":\"The EMA has published version 1.2 of the document &#8216;Guidance on the electronic submission of information on investigational medicinal products for human use in the XEVMPD&#8217; (T1, T2, T3).\",\"datePublished\":\"2024-02-14T06:21:35+00:00\",\"dateModified\":\"2024-11-04T14:36:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/ocvigilance.com\\\/en\\\/the-ema-has-published-version-1-2-of-the-document-guidance-on-the-electronic-submission-of-information-on-investigational-medicinal-products-for-human-use-in-the-xevmpd-t1-t2-t3\\\/\"},\"wordCount\":30,\"publisher\":{\"@id\":\"https:\\\/\\\/ocvigilance.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/ocvigilance.com\\\/en\\\/the-ema-has-published-version-1-2-of-the-document-guidance-on-the-electronic-submission-of-information-on-investigational-medicinal-products-for-human-use-in-the-xevmpd-t1-t2-t3\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ocvigilance.com\\\/wp-content\\\/uploads\\\/2024\\\/06\\\/La-EMA-ha-publicado-la-version-1.2-del-documento-Guidance-on-the-electronic-submission-of-information-on-investigational-medicinal-products-for-human-use-in-the-XEVMPD.-T1-T2-T3.avif\",\"articleSection\":[\"Medicamentos de uso humano\",\"Medicines for human use\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ocvigilance.com\\\/en\\\/the-ema-has-published-version-1-2-of-the-document-guidance-on-the-electronic-submission-of-information-on-investigational-medicinal-products-for-human-use-in-the-xevmpd-t1-t2-t3\\\/\",\"url\":\"https:\\\/\\\/ocvigilance.com\\\/en\\\/the-ema-has-published-version-1-2-of-the-document-guidance-on-the-electronic-submission-of-information-on-investigational-medicinal-products-for-human-use-in-the-xevmpd-t1-t2-t3\\\/\",\"name\":\"Guidance on the electronic submission of information on investigational medicinal products for human use in the XEVMPD | OC Vigilance\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ocvigilance.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/ocvigilance.com\\\/en\\\/the-ema-has-published-version-1-2-of-the-document-guidance-on-the-electronic-submission-of-information-on-investigational-medicinal-products-for-human-use-in-the-xevmpd-t1-t2-t3\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/ocvigilance.com\\\/en\\\/the-ema-has-published-version-1-2-of-the-document-guidance-on-the-electronic-submission-of-information-on-investigational-medicinal-products-for-human-use-in-the-xevmpd-t1-t2-t3\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ocvigilance.com\\\/wp-content\\\/uploads\\\/2024\\\/06\\\/La-EMA-ha-publicado-la-version-1.2-del-documento-Guidance-on-the-electronic-submission-of-information-on-investigational-medicinal-products-for-human-use-in-the-XEVMPD.-T1-T2-T3.avif\",\"datePublished\":\"2024-02-14T06:21:35+00:00\",\"dateModified\":\"2024-11-04T14:36:16+00:00\",\"description\":\"The EMA has published version 1.2 of the document 'Guidance on the electronic submission of information on investigational medicinal products for human use in the XEVMPD' (T1, T2, T3) All the information!\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ocvigilance.com\\\/en\\\/the-ema-has-published-version-1-2-of-the-document-guidance-on-the-electronic-submission-of-information-on-investigational-medicinal-products-for-human-use-in-the-xevmpd-t1-t2-t3\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ocvigilance.com\\\/en\\\/the-ema-has-published-version-1-2-of-the-document-guidance-on-the-electronic-submission-of-information-on-investigational-medicinal-products-for-human-use-in-the-xevmpd-t1-t2-t3\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/ocvigilance.com\\\/en\\\/the-ema-has-published-version-1-2-of-the-document-guidance-on-the-electronic-submission-of-information-on-investigational-medicinal-products-for-human-use-in-the-xevmpd-t1-t2-t3\\\/#primaryimage\",\"url\":\"https:\\\/\\\/ocvigilance.com\\\/wp-content\\\/uploads\\\/2024\\\/06\\\/La-EMA-ha-publicado-la-version-1.2-del-documento-Guidance-on-the-electronic-submission-of-information-on-investigational-medicinal-products-for-human-use-in-the-XEVMPD.-T1-T2-T3.avif\",\"contentUrl\":\"https:\\\/\\\/ocvigilance.com\\\/wp-content\\\/uploads\\\/2024\\\/06\\\/La-EMA-ha-publicado-la-version-1.2-del-documento-Guidance-on-the-electronic-submission-of-information-on-investigational-medicinal-products-for-human-use-in-the-XEVMPD.-T1-T2-T3.avif\",\"width\":2070,\"height\":1380},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ocvigilance.com\\\/en\\\/the-ema-has-published-version-1-2-of-the-document-guidance-on-the-electronic-submission-of-information-on-investigational-medicinal-products-for-human-use-in-the-xevmpd-t1-t2-t3\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/ocvigilance.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"The EMA has published version 1.2 of the document &#8216;Guidance on the electronic submission of information on investigational medicinal products for human use in the XEVMPD&#8217; (T1, T2, T3).\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ocvigilance.com\\\/#website\",\"url\":\"https:\\\/\\\/ocvigilance.com\\\/\",\"name\":\"OC Vigilance\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/ocvigilance.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ocvigilance.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/ocvigilance.com\\\/#organization\",\"name\":\"OC Vigilance\",\"url\":\"https:\\\/\\\/ocvigilance.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/ocvigilance.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/ocvigilance.com\\\/wp-content\\\/uploads\\\/2024\\\/06\\\/logo-oscuro.png\",\"contentUrl\":\"https:\\\/\\\/ocvigilance.com\\\/wp-content\\\/uploads\\\/2024\\\/06\\\/logo-oscuro.png\",\"width\":250,\"height\":100,\"caption\":\"OC Vigilance\"},\"image\":{\"@id\":\"https:\\\/\\\/ocvigilance.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/ocvigilance.com\\\/#\\\/schema\\\/person\\\/1305e83051c56e0ccbcdbf88c278aa8f\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/ocvigilance.com\\\/wp-content\\\/litespeed\\\/avatar\\\/c3123898c78b3015503ed03020e30fa5.jpg?ver=1794859654\",\"url\":\"https:\\\/\\\/ocvigilance.com\\\/wp-content\\\/litespeed\\\/avatar\\\/c3123898c78b3015503ed03020e30fa5.jpg?ver=1794859654\",\"contentUrl\":\"https:\\\/\\\/ocvigilance.com\\\/wp-content\\\/litespeed\\\/avatar\\\/c3123898c78b3015503ed03020e30fa5.jpg?ver=1794859654\",\"caption\":\"admin\"},\"sameAs\":[\"https:\\\/\\\/ocvigilance.virtualcivan.es\"],\"url\":\"https:\\\/\\\/ocvigilance.com\\\/en\\\/author\\\/ocvigilance_vyc\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Guidance on the electronic submission of information on investigational medicinal products for human use in the XEVMPD | OC Vigilance","description":"The EMA has published version 1.2 of the document 'Guidance on the electronic submission of information on investigational medicinal products for human use in the XEVMPD' (T1, T2, T3) All the information!","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ocvigilance.com\/en\/the-ema-has-published-version-1-2-of-the-document-guidance-on-the-electronic-submission-of-information-on-investigational-medicinal-products-for-human-use-in-the-xevmpd-t1-t2-t3\/","og_locale":"en_US","og_type":"article","og_title":"Guidance on the electronic submission of information on investigational medicinal products for human use in the XEVMPD | OC Vigilance","og_description":"The EMA has published version 1.2 of the document 'Guidance on the electronic submission of information on investigational medicinal products for human use in the XEVMPD' (T1, T2, T3) All the information!","og_url":"https:\/\/ocvigilance.com\/en\/the-ema-has-published-version-1-2-of-the-document-guidance-on-the-electronic-submission-of-information-on-investigational-medicinal-products-for-human-use-in-the-xevmpd-t1-t2-t3\/","og_site_name":"OC Vigilance","article_published_time":"2024-02-14T06:21:35+00:00","article_modified_time":"2024-11-04T14:36:16+00:00","author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ocvigilance.com\/en\/the-ema-has-published-version-1-2-of-the-document-guidance-on-the-electronic-submission-of-information-on-investigational-medicinal-products-for-human-use-in-the-xevmpd-t1-t2-t3\/#article","isPartOf":{"@id":"https:\/\/ocvigilance.com\/en\/the-ema-has-published-version-1-2-of-the-document-guidance-on-the-electronic-submission-of-information-on-investigational-medicinal-products-for-human-use-in-the-xevmpd-t1-t2-t3\/"},"author":{"name":"admin","@id":"https:\/\/ocvigilance.com\/#\/schema\/person\/1305e83051c56e0ccbcdbf88c278aa8f"},"headline":"The EMA has published version 1.2 of the document &#8216;Guidance on the electronic submission of information on investigational medicinal products for human use in the XEVMPD&#8217; (T1, T2, T3).","datePublished":"2024-02-14T06:21:35+00:00","dateModified":"2024-11-04T14:36:16+00:00","mainEntityOfPage":{"@id":"https:\/\/ocvigilance.com\/en\/the-ema-has-published-version-1-2-of-the-document-guidance-on-the-electronic-submission-of-information-on-investigational-medicinal-products-for-human-use-in-the-xevmpd-t1-t2-t3\/"},"wordCount":30,"publisher":{"@id":"https:\/\/ocvigilance.com\/#organization"},"image":{"@id":"https:\/\/ocvigilance.com\/en\/the-ema-has-published-version-1-2-of-the-document-guidance-on-the-electronic-submission-of-information-on-investigational-medicinal-products-for-human-use-in-the-xevmpd-t1-t2-t3\/#primaryimage"},"thumbnailUrl":"https:\/\/ocvigilance.com\/wp-content\/uploads\/2024\/06\/La-EMA-ha-publicado-la-version-1.2-del-documento-Guidance-on-the-electronic-submission-of-information-on-investigational-medicinal-products-for-human-use-in-the-XEVMPD.-T1-T2-T3.avif","articleSection":["Medicamentos de uso humano","Medicines for human use"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/ocvigilance.com\/en\/the-ema-has-published-version-1-2-of-the-document-guidance-on-the-electronic-submission-of-information-on-investigational-medicinal-products-for-human-use-in-the-xevmpd-t1-t2-t3\/","url":"https:\/\/ocvigilance.com\/en\/the-ema-has-published-version-1-2-of-the-document-guidance-on-the-electronic-submission-of-information-on-investigational-medicinal-products-for-human-use-in-the-xevmpd-t1-t2-t3\/","name":"Guidance on the electronic submission of information on investigational medicinal products for human use in the XEVMPD | OC Vigilance","isPartOf":{"@id":"https:\/\/ocvigilance.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ocvigilance.com\/en\/the-ema-has-published-version-1-2-of-the-document-guidance-on-the-electronic-submission-of-information-on-investigational-medicinal-products-for-human-use-in-the-xevmpd-t1-t2-t3\/#primaryimage"},"image":{"@id":"https:\/\/ocvigilance.com\/en\/the-ema-has-published-version-1-2-of-the-document-guidance-on-the-electronic-submission-of-information-on-investigational-medicinal-products-for-human-use-in-the-xevmpd-t1-t2-t3\/#primaryimage"},"thumbnailUrl":"https:\/\/ocvigilance.com\/wp-content\/uploads\/2024\/06\/La-EMA-ha-publicado-la-version-1.2-del-documento-Guidance-on-the-electronic-submission-of-information-on-investigational-medicinal-products-for-human-use-in-the-XEVMPD.-T1-T2-T3.avif","datePublished":"2024-02-14T06:21:35+00:00","dateModified":"2024-11-04T14:36:16+00:00","description":"The EMA has published version 1.2 of the document 'Guidance on the electronic submission of information on investigational medicinal products for human use in the XEVMPD' (T1, T2, T3) All the information!","breadcrumb":{"@id":"https:\/\/ocvigilance.com\/en\/the-ema-has-published-version-1-2-of-the-document-guidance-on-the-electronic-submission-of-information-on-investigational-medicinal-products-for-human-use-in-the-xevmpd-t1-t2-t3\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ocvigilance.com\/en\/the-ema-has-published-version-1-2-of-the-document-guidance-on-the-electronic-submission-of-information-on-investigational-medicinal-products-for-human-use-in-the-xevmpd-t1-t2-t3\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ocvigilance.com\/en\/the-ema-has-published-version-1-2-of-the-document-guidance-on-the-electronic-submission-of-information-on-investigational-medicinal-products-for-human-use-in-the-xevmpd-t1-t2-t3\/#primaryimage","url":"https:\/\/ocvigilance.com\/wp-content\/uploads\/2024\/06\/La-EMA-ha-publicado-la-version-1.2-del-documento-Guidance-on-the-electronic-submission-of-information-on-investigational-medicinal-products-for-human-use-in-the-XEVMPD.-T1-T2-T3.avif","contentUrl":"https:\/\/ocvigilance.com\/wp-content\/uploads\/2024\/06\/La-EMA-ha-publicado-la-version-1.2-del-documento-Guidance-on-the-electronic-submission-of-information-on-investigational-medicinal-products-for-human-use-in-the-XEVMPD.-T1-T2-T3.avif","width":2070,"height":1380},{"@type":"BreadcrumbList","@id":"https:\/\/ocvigilance.com\/en\/the-ema-has-published-version-1-2-of-the-document-guidance-on-the-electronic-submission-of-information-on-investigational-medicinal-products-for-human-use-in-the-xevmpd-t1-t2-t3\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/ocvigilance.com\/en\/"},{"@type":"ListItem","position":2,"name":"The EMA has published version 1.2 of the document &#8216;Guidance on the electronic submission of information on investigational medicinal products for human use in the XEVMPD&#8217; (T1, T2, T3)."}]},{"@type":"WebSite","@id":"https:\/\/ocvigilance.com\/#website","url":"https:\/\/ocvigilance.com\/","name":"OC Vigilance","description":"","publisher":{"@id":"https:\/\/ocvigilance.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ocvigilance.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/ocvigilance.com\/#organization","name":"OC Vigilance","url":"https:\/\/ocvigilance.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ocvigilance.com\/#\/schema\/logo\/image\/","url":"https:\/\/ocvigilance.com\/wp-content\/uploads\/2024\/06\/logo-oscuro.png","contentUrl":"https:\/\/ocvigilance.com\/wp-content\/uploads\/2024\/06\/logo-oscuro.png","width":250,"height":100,"caption":"OC Vigilance"},"image":{"@id":"https:\/\/ocvigilance.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/ocvigilance.com\/#\/schema\/person\/1305e83051c56e0ccbcdbf88c278aa8f","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ocvigilance.com\/wp-content\/litespeed\/avatar\/c3123898c78b3015503ed03020e30fa5.jpg?ver=1794859654","url":"https:\/\/ocvigilance.com\/wp-content\/litespeed\/avatar\/c3123898c78b3015503ed03020e30fa5.jpg?ver=1794859654","contentUrl":"https:\/\/ocvigilance.com\/wp-content\/litespeed\/avatar\/c3123898c78b3015503ed03020e30fa5.jpg?ver=1794859654","caption":"admin"},"sameAs":["https:\/\/ocvigilance.virtualcivan.es"],"url":"https:\/\/ocvigilance.com\/en\/author\/ocvigilance_vyc\/"}]}},"_links":{"self":[{"href":"https:\/\/ocvigilance.com\/en\/wp-json\/wp\/v2\/posts\/1620","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ocvigilance.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ocvigilance.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ocvigilance.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/ocvigilance.com\/en\/wp-json\/wp\/v2\/comments?post=1620"}],"version-history":[{"count":1,"href":"https:\/\/ocvigilance.com\/en\/wp-json\/wp\/v2\/posts\/1620\/revisions"}],"predecessor-version":[{"id":1622,"href":"https:\/\/ocvigilance.com\/en\/wp-json\/wp\/v2\/posts\/1620\/revisions\/1622"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ocvigilance.com\/en\/wp-json\/wp\/v2\/media\/1486"}],"wp:attachment":[{"href":"https:\/\/ocvigilance.com\/en\/wp-json\/wp\/v2\/media?parent=1620"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ocvigilance.com\/en\/wp-json\/wp\/v2\/categories?post=1620"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ocvigilance.com\/en\/wp-json\/wp\/v2\/tags?post=1620"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}